BACKGROUND
The main risk factor for gastric cancer (GC) is inflammation driven by Helicobacter pylori (H. pylori) infection. Despite growing use of immunotherapies targeting the tumor inflammatory microenvironment, responses remain suboptimal, highlighting the need to define inflammatory drivers and improve patient stratification.
METHODS
We assessed the role of R-spondin 3 (RSPO3), a stroma-secreted Wnt potentiator, in a Caucasian tissue microarray of 277 chemotherapy-naïve GC patients by associating RSPO3 expression with tumor inflammation, tumor stage, and survival. To mechanistically explore the role of Rspo3 in immune cell infiltration, we used conditional mouse models with stromal Rspo3 overexpression or knockout and infected them with H. pylori. We conditionally depleted the epithelial Rspo3 receptors Lgr4 and Lgr5 in mice to assess the mode of Rspo3 signaling. Findings were validated by generating a single-cell atlas from The Cancer Genome Atlas and performing gastric cancer transcriptome analysis.
RESULTS
Tumor RSPO3 expression positively associated with mucosal T-cell infiltration and combined positive score, a phenotype specific to intestinal-type GC. In mice, stromal Rspo3 promoted T-cell infiltration with increased interferon-γ signaling and PD-L1 expression in H. pylori-driven precancerous lesions. Epithelial depletion of Lgr4/5 reduced gastric T-cell infiltration and PD-L1 expression.
CONCLUSIONS
In mice, mesenchymal-epithelial RSPO3-LGR4/5 signaling drives inflammation and enhances immune checkpoint signaling in precancerous lesions. Positive associations between RSPO3 expression and inflammation suggest that RSPO3 signaling contributes to shaping the immune microenvironment of human intestinal-type GC.
Anne-Sophie Fischer, Alexander Arnold, Hilmar Berger et al.· Gastric Cancer· 0 citations
The overall immunogenicity and prognostic relevance of immune markers in dMMR/MSI-H CRC depend on tumor stage, and immune profiling could be used for early-stage patient stratification and also suggests the potential benefit of early immunotherapeutic intervention.
Sabina Niyazova, C. Sers, H. Bläker et al.· Oncoimmunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.